Johnson & Johnson (NYSE:JNJ) Trading Up 0.7% – Should You Buy?

Johnson & Johnson (NYSE:JNJGet Free Report)’s share price traded up 0.7% during trading on Tuesday . The company traded as high as $148.86 and last traded at $148.00. 2,339,691 shares traded hands during mid-day trading, a decline of 71% from the average session volume of 8,031,792 shares. The stock had previously closed at $147.03.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on JNJ. Morgan Stanley dropped their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Thursday. Raymond James cut their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday. Barclays decreased their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating for the company in a research note on Tuesday. Guggenheim raised their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Finally, Leerink Partners decreased their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday. Nine analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $170.06.

Read Our Latest Analysis on Johnson & Johnson

Johnson & Johnson Price Performance

The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a market cap of $352.91 billion, a PE ratio of 21.21, a P/E/G ratio of 2.52 and a beta of 0.51. The business’s fifty day moving average is $148.10 and its 200-day moving average is $156.05.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22,438,500 billion. During the same period last year, the business posted $2.29 earnings per share. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, research analysts predict that Johnson & Johnson will post 9.95 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.38%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Summit Wealth Partners LLC raised its position in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Summit Wealth Partners LLC now owns 10,007 shares of the company’s stock worth $1,463,000 after purchasing an additional 61 shares during the last quarter. Powers Advisory Group LLC raised its holdings in shares of Johnson & Johnson by 0.6% during the third quarter. Powers Advisory Group LLC now owns 9,489 shares of the company’s stock valued at $1,538,000 after acquiring an additional 61 shares during the last quarter. Eagle Wealth Strategies LLC lifted its position in shares of Johnson & Johnson by 2.8% in the third quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company’s stock valued at $372,000 after acquiring an additional 63 shares in the last quarter. Knuff & Co LLC grew its holdings in shares of Johnson & Johnson by 0.7% during the third quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock worth $1,534,000 after buying an additional 64 shares in the last quarter. Finally, Perkins Coie Trust Co lifted its stake in shares of Johnson & Johnson by 1.8% in the third quarter. Perkins Coie Trust Co now owns 3,705 shares of the company’s stock worth $600,000 after buying an additional 65 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Company Profile

(Get Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Recommended Stories

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.